LeafNLP Demos
Back to explore

Report #2884156

Received Feb 4, 2026

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Female
Age
73 yrs
State
CT
Recovered
Unknown
Vaccinated
Jan 30, 2026
Onset
Jan 30, 2026
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
RSVRSV (AREXVY)GLAXOSMITHKLINE BIOLOGICALS15N79ZSC

Symptoms (1)

Incorrect route of product administration

Symptom narrative

Inappropriate Route of Administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of intramuscular formulation administered by other route in a 73-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 5N79Z, expiry date 12-DEC-2026) for prophylaxis. On 30-JAN-2026, the patient received the 1st dose of Arexvy (subcutaneous). On 30-JAN-2026, an unknown time after receiving Arexvy, the patient experienced intramuscular formulation administered by other route (Verbatim: Inappropriate Route of Administration). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK receipt date: 30-JAN-2026 A pharmacist called to get guidance after he administered a dose of Arexvy and immediately realized there was a bubble below the skin of the patient, like if it was administered Subcutaneous instead of the recommended Intramuscular route. The reporter wanted to know if it was considered a valid shot.